All In Biotech

Drug Trial Radar · NCT01054443

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy

Last checked: Nov 20, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

20

Actual

Start

Mar 18, 2010

Primary completion

Nov 24, 2010

Study completion Nov 24, 2010

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Jan 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

  • PlaceboDrug

    Tablet

  • LusutrombopagDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a ResponseTime frame: Week 6

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator

    Anaheim, California

  • Investigator

    Los Angeles, California

  • Investigator

    Washington D.C., District of Columbia

  • Investigator

    Boynton Beach, Florida

  • Investigator

    Jacksonville, Florida

  • Investigator

    Atlanta, Georgia

  • Investigator

    Riverdale, Georgia

  • Investigator

    Metairie, Louisiana

  • Investigator

    Bethesda, Maryland

  • Investigator

    Boston, Massachusetts

  • Investigator

    Jefferson City, Missouri

  • Investigator

    Kansas City, Missouri

  • Investigator

    New Brunswick, New Jersey

  • Investigator

    New York, New York

  • Investigator

    New York, New York

  • Investigator

    Cleveland, Ohio

  • Investigator

    San Antonio, Texas

  • Investigator

    Salt Lake City, Utah

  • Investigator

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.